Cellectis consolidated net loss $33 million in second quarter
FDA approved IND for UCARTCS1 – first allogeneic CAR T-cell product candidate in multiple myeloma (MM) Ongoing construction of in-house…
Pharmaceuticals, Biotechnology and Life Sciences
FDA approved IND for UCARTCS1 – first allogeneic CAR T-cell product candidate in multiple myeloma (MM) Ongoing construction of in-house…
– Progressing our lead program, AB928, a potential best-in-class dual A2a/A2b receptor antagonist, into multiple dose-expansion cohorts in 2H19, including…
Conference Call Scheduled for Today, August 6, 2019, at 3:30 PM CT (4:30 PM ET) Revenues of $68.2 million increased…
BRISBANE, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that CEO Sandy Macrae will present at…
IMVEXXY® Net Revenue $3.1 Million for the Second Quarter of 2019 Total Net Revenue for the Second Quarter of 2019…
– Fully-enrolled AURORA Phase 3 trial in lupus nephritis continues on track with results anticipated in late 2019 – –…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced…
Webcast and Conference Call today at 4:30 p.m. ET Royalty revenue for the quarter was $44.4 million Phase 2a NASH…
DUBLIN–(BUSINESS WIRE)–The “Oligonucleotide Synthesis Market by Product, Type (Custom, Pre design), Application (PCR, DNA, RNAi, Research, Therapeutic), End User –…
BEDFORD, Mass.–(BUSINESS WIRE)–#dravet–Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of…